← Back to Screener
Alzamend Neuro, Inc. Common Stock (ALZN)
Price$1.00
Favorite Metrics
Price vs S&P 500 (26W)-63.67%
Price vs S&P 500 (4W)-52.70%
Market Capitalization$3.88M
All Metrics
Book Value / Share (Quarterly)$0.57
P/TBV (Annual)2.19x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.62
Price vs S&P 500 (YTD)-46.60%
EPS (TTM)$-3.76
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-3.76
EPS (Annual)$-10.02
ROI (Annual)-113.78%
Cash / Share (Quarterly)$0.71
ROA (Last FY)-98.09%
EBITD / Share (TTM)$-2.77
ROE (5Y Avg)-296.65%
Cash Flow / Share (Annual)$-8.82
P/B Ratio1.78x
P/B Ratio (Quarterly)3.78x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-249.41x
ROA (TTM)-140.39%
EPS Incl Extra (Annual)$-10.02
Current Ratio (Annual)6.58x
Quick Ratio (Quarterly)1.46x
3-Month Avg Trading Volume0.12M
52-Week Price Return-85.63%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.02
52-Week High$8.22
EPS Excl Extra (Annual)$-10.02
26-Week Price Return-59.68%
Quick Ratio (Annual)6.22x
13-Week Price Return-56.22%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.99x
Enterprise Value$1.168
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.07
3-Month Return Std Dev104.68%
Net Income / Employee (TTM)$-2
ROE (Last FY)-113.78%
Net Interest Coverage (Annual)-1007.87x
EPS Basic Excl Extra (Annual)$-10.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.76
ROI (TTM)-177.48%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.47
Price vs S&P 500 (52W)-115.46%
Year-to-Date Return-43.96%
5-Day Price Return13.02%
EPS Normalized (Annual)$-10.02
ROA (5Y Avg)-436.63%
Month-to-Date Return-3.77%
Cash Flow / Share (TTM)$-2.35
EBITD / Share (Annual)$-9.86
ROI (5Y Avg)-289.38%
EPS Basic Excl Extra (TTM)$-3.76
P/B Ratio (Annual)1.10x
Book Value / Share (Annual)$5.10
Price vs S&P 500 (13W)-56.91%
Beta0.02x
Revenue / Share (TTM)$0.00
ROE (TTM)-177.48%
52-Week Low$0.84
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALZNAlzamend Neuro, Inc. Common Stock | — | — | — | — | $1.00 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Alzamend Neuro is an early-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases and psychiatric disorders, with a focus on Alzheimer's disease. Its pipeline consists of AL001, a patented lithium-based ionic cocrystal technology, and AL002, a cell-based therapeutic vaccine designed to restore immune response against Alzheimer's.